Initiative

• NTT launched Scale Academy as part of its enterprise AI and security initiatives during the two-week period beginning April 13, 2026. • The academy program targets organizations seeking to develop internal capabilities around artificial intelligence adoption and implementation. • The initiative reflects growing enterprise demand for structured training programs to build AI competency across workforce and organizational functions.

• Pharmaceutical giants Eli Lilly and Pfizer announced a strategic research collaboration focusing on oncology and immunology, with combined commitments totaling $4.8 billion over five years to accelerate drug development and clinical trial timelines. • The partnership will leverage Eli Lilly's metabolic disease expertise and Pfizer's vaccine platform capabilities to pursue combination therapies for hard-to-treat cancers, with initial clinical trials expected to commence in mid-2027. • Industry analysts view the deal as emblematic of Big Pharma consolidating R&D resources amid rising drug development costs exceeding $2.6 billion per approved medication, while also signaling confidence in oncology market growth.

• President Trump has moved to fast-track psychedelic research as part of his administration's policy agenda, marking a significant shift in federal drug policy priorities. • Former Arizona Senator Kyrsten Sinema has publicly applauded the initiative as a "bold step forward" in medical research on Fox & Friends Weekend. • The accelerated psychedelic research program represents an innovative approach to mental health treatment and scientific advancement under the Trump administration.

• Salesforce announced Headless 360 on Wednesday, enabling AI agents to access its platform capabilities via APIs, MCP tools, or CLI commands. • The initiative marks the company's most ambitious architectural transformation in 27 years, aiming to enhance AI integration across its ecosystem. • This development matters as it positions Salesforce as a leader in AI-driven enterprise software, potentially accelerating agentic AI adoption in business operations.

• Colombian President Gustavo Petro unveiled a comprehensive land redistribution program Friday affecting 3.2 million hectares, targeting decades of unequal land concentration and addressing root causes of internal conflict. • The reform package includes restitution for peasants and Indigenous communities, tax incentives for productive small-scale agriculture, and international financing commitments worth $4.8 billion over five years. • The announcement occurs during peace negotiations with remaining ELN guerrilla factions, with analysts viewing land reform as critical to achieving durable peace and reducing rural poverty affecting 38% of the population.

• The FDA announced it will issue national priority vouchers for three psychedelic drugs next week, marking the first time the agency has fast-tracked any psychedelics for review under Trump's executive order on mental health reform. • The vouchers can compress FDA review timelines from several months to just weeks, according to FDA Commissioner Marty Makary, if the drugs align with national priorities. • Trump's order directs $50 million in federal funding to states developing psychedelic treatment programs and establishes a federal-state partnership for technical assistance and data sharing.

• The FDA announced the first ibogaine investigational new drug application as part of Trump's mental health executive order accelerating psychedelic drug approvals and research pathways. • HHS will coordinate with the FDA and DEA to expedite research approval and clinical trial access for emerging mental health treatments under strict medical supervision and scientific oversight. • The initiative specifically targets treatment-resistant conditions and addresses mental health needs among veterans and patients who have not responded to conventional therapies.

• The U.S. National Institute of Standards and Technology announced initiatives on April 7, 2026, to define security standards for AI agents that act autonomously via APIs. • These agents create new attack surfaces where AI decisions directly impact real-world operations, requiring governance to mitigate organizational risks. • The move addresses vulnerabilities as governments accelerate AI deployment despite security gaps in federal projects.